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A monoclonal antibody against thromboxane B, which may be used in standard fluid phase radioimmunoassays with 
a detection limit of around 40 pg and a binding affinity of 1.98 x log M-i is described. Limited crossreactivity could 
be observed only with structurally closely related compounds uch as 2,3-dinor-thromboxane B, (8.9@, thromboxane 
B, (15.7%) and thromboxane & (39.7%). Detectable crossreactivity with 1 I-dehydro-thromboxane %, o-carboxy-throm- 
boxane BZ, o-hydroxy-thromboxane Bz, prostaglandins of the D-, E- and F-type as well as metabolites of prostacyclin 
was lacking. The monoclonal anti-thromboxane B, antibody proved well suited for measuring the thromboxane B2 con- 
tent in tissue culture supernatants as well as in human serum. 
Thromboxane 4; Monoclonal antibody; Radioimmunoassay 
1. INTRODUCTION 
Thromboxanes (TXs) comprise a distinct 
subclass of eicosanoids known to derive from 
platelets and to regulate the function of these 
blood particles. The biologically active TXAz 
causes platelet aggregation and may play an impor- 
tant role in acute coronary disease 111. 
Measurements of TXs have also attained clinical 
importance for monitoring graft rejection follow- 
ing kidney transplantation [2]. However, TXA, is 
very unstable, with a half-life of 30-40 s at 37°C 
and physiological pH [3], and is quickly metabo- 
lized into the inactive but stable TXBz. Therefore 
TXB2 is widely used for indirect measurements of 
TXAz production in biological samples. 
Many sensitive radioimmunoassays (RIAs) have 
been developed using polyclonal antibodies 
(PABs) from rabbit immunized with TXBz. These 
PABs are very sensitive in this system and show lit- 
tle crossreaction with most prostaglandins, but, 
when tested, have been less specific against TXBz 
metabolites. Many PABs show considerable 
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crossreaction with 2,3-dinor-TXBz, which is pre- 
sent in blood [4,5], and, in even larger amounts, in 
urine [5,6]. 
Monoclonal antibodies (MABs) have been pro- 
duced against prostaglandin E2 [7-91, and can 
show good sensitivity and high specificity against 
related eicosanoids [7]. We, therefore, have 
developed a MAB against TXB2 suitable for 
measurement of TXA2 at biologically relevant con- 
centrations in conventional fluid RIAs. 
2. MATERIALS AND METHODS 
2.1. Materials 
TXBz and other prostanoids were purchased from Sigma 
(Taufkirchen, FRG). Metabolites of TXBz were the generous 
gift of Dr C.O. Meese (Dr Margarete Fischer-Bosch, Institute 
of Clinical Pharmacology, Stuttgart, FRG), synthesized accor- 
ding to Fiirst [lo], Meese et al. [ll], Schweer et al. [12], and 
Meese (in preparation). The radioantigen [5,6,8,9,11,12,14, 
IS(n)-‘H]TXBz (spec. act. [15(n)-3H]TXBz 189 Ci/mmol) and 
the [‘H]TXBz assay system (TRK 780) were purchased from 
Amersham Buchler (Braunschweig, FRG). 
2.2. Hybridoma production and selection 
Approx. g-week-old Balb/c mice were immunized each time 
with 20/g TXBz-BSA conjugate according to the method 
described [7]. Mice showing high titers of TXBz binding activity 
in serum were bled, the spleen removed and the spleen cells 
fused with the aminopterin sensitive myeloma cell line X63 
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Table 1 
Characteristics of monoclonal antibody against thromboxane 
Bz (4E-TBRr) 
Prostaglandins Crossreaction (I&O) 
Vs) 
TXB, 
TXBz 
TXBs 
2,3-Dinor TXBz 
1 I-Dehydro-TXBr 
I I-Dehydro-TXBz 
w-Carboxy-TXBz 
w-Hydroxy-TXBz 
PGDz 
PGF2, 
PGEz 
6-Keto-PGFr, 
Sensitivity (ng) 
lmmunoglobulin subclass 
15.7 
100 (0.40 ng) 
39.7 
8.6 
0.5 
0.7 
<O.l 
<O.l 
<O.l 
<O.l 
<O.l 
<O.l 
0.04 
lgG2a 
Ag8.653 (G. Kohler, MPI, Freiburg, FRG) by the addition of 
polyethylene glycol 4000 (Merck, Darmstadt, FRG). After 
isolating hybridoma cells employing a selection medium con- 
taining hypoxanthine, aminopterin and thymidine, clones 
showing TXBz binding activity were selected. Subclones were 
produced on feeder layers of mouse peritoneal macrophages by 
two cycles of limiting dilution cloning. Cultures were expanded 
in Dulbecco’s modified Eagle medium completed with sodium 
pyruvate, L-glutamine, 2-mercaptoethanol and 20% of fetal 
calf serum but without phenol red. The culture supernatants 
were collected and stored after lyophilization. For further use 
1 mg of the lyophilized powder was dissolved in 1 ml of distilled 
water to prepare a stock solution of MAB. 
2.3. Characterization of MAB-TXB2 
The MAB containing culture supernatants were checked for 
sensitivity and for binding specificity by standard fluid phase 
RlAs. The total sample volume of 1 ml contained about 10~1 
MAB stock solution (-25% binding). Charcoal (100 ,~l of 3% 
solution) was used to separate the bound and unbound com- 
ponents. RIA with PAB (sensitivity 5 pg/sample) was carried 
out according to the kit description from Amersham with a 
sample volume of 300 ,uI and 1000 pl of dextran-coated charcoal 
used to separate bound from free TXBz. The lg subclass was 
identified using a hybridoma sub-isotyping kit (Calbiochem, 
Frankfurt, FRG). The MAB was also substituted for PABs in 
routine assays of the supernatants of macrophages timulated 
to release icosanoids (13) as well as in analysis of blood serum. 
For the latter experiments 2 ml venous blood was collected 
every 15 min using an Abbocath-T (20G x 32 mm, Abbott, 
Ireland), and directly dropped into tubes containing 100 ~1 in- 
domethacin (10m4 mol/l). After 30 min incubation at 37°C and 
centrifugation the serum was frozen and stored at - 70°C until 
the measurement of TXBZ in fluid phase RIA. Platelet aggrega- 
tion experiments were done with 1 ml platelet rich plasma 
stimulated by 5 ~1 arachidonic acid (76 x lo-’ mol/l) using a 
whole blood agrometer (Coulter, Krefeld, FRG). Aggregation 
was measured after addition of MAB-TXBZ using 2-1000 fig of 
the lyophilized culture supernatant. 
3. RESULTS 
The characteristics of the new MAB-TXBZ (4E- 
TBR,) are compiled in table 1. The MAB belongs 
to the IgG2a subclass, and the affinity defined by 
Thronboxone B2 r nci I 
Fig.1. Standard curves describing the binding of TXBz to the MAB-TXBz (4E-TBRr) using phosphate buffered saline 
supplemented with 10% plasma (0) and 10% serum (0) in a conventional fluid phase RIA. 
alone (o), or 
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Fig.2. Recovery of TXBZ with h4AB-TXBz W-TBW in a 
conventional fluid phase RIA. 
Scatchard analysis is 1.98 x lo9 M-l. Employing 
conventional fluid phase RIA with a 1 ml sample 
volume, the detection limit of TXBz was found to 
be about 40 pg. 
We first examined the crossreactivity of the 
MAB against known metabolites of TXB2. 
Modification of the a-chain usually causes high 
crossreactivity in PABs. Nevertheless, this MAB 
shows very low crossreactivity of 8.9% with the 
important TXB2 metabolite 2,3-dinor-TXB2. 
Reduction of the 5-6 bond to TXBl also results in 
low crossreactivity (15.7%). Upon analyzing 
metabolites with variations in the ring structure or 
with alterations in the w-chain, we found less than 
1% crossreactivity in each case. TXB3 is an excep- 
tion with a crossreactivity of 39.7%. Crossreactivi- 
ty with prostaglandins was negligible. 
To determine crossreactivity with the biological- 
ly active but unstable TXA2, we tested whether our 
MAB-TXB2 interferes with platelet aggregation in- 
itiated by arachidonic acid, since it is known that 
arachidonic acid-induced platelet aggregation is 
caused by TXA2 [3]. Concentrations of MAB- 
TXB2 which bound more than 55% TXB;! within 
the first minute did not interfere with arachidonic 
acid-induced platelet aggregation in platelet rich 
plasma. This suggests that there is no prominent 
crossreactivity with TXA2. 
Some PABs change their sensitivity in assays 
containing biological fluids. In standard ex- 
periments the binding of TXB2 to the MAB was 
not measurably influenced by the addition of up to 
10% plasma or serum to the incubation mixture 
(fig. 1). To validate the utility of the new MAB, we 
tested its accuracy in RIA by adding known 
amounts of TXBz. Essentially 100% recovery was 
found over the tested concentration range (fig.2). 
The calcium ionophore A23 187 is widely used to 
investigate the effect of drugs on the production of 
prostaglandin E2 and leukotrienes by mouse 
peritoneal macrophages. We have found this pro- 
cedure to also produce TXs and have used it to 
compare our MAB-TXBz with a commercial PAB 
assay system for TXB;?. We examined two drugs, 
the non-steroidal anti-inflammatory drug in- 
domethacin, an inhibitor of the cyclooxygenase n- 
zyme, and dazmegrel, a selective inhibitor of the 
TX-synthetase enzyme (fig.3). Both inhibitors 
were studied at several concentrations. The data 
obtained from comparing the MAB and the PAB 
RIA system (see section 2) demonstrate agood cor- 
relation between the two RIA results. Both RIAs 
showed inhibition of the cyclooxygenase nzyme 
by indomethacin at a concentration of 10e6 M and 
the stepwise loss of inhibition up to a concentra- 
tion of 10e9 M, with a correlation between the two 
systems of r = 0.98. The effect of dazmegrel as 
blocking agent was demonstrated up to 10e7 M, 
while there was no inhibition at lo-’ M. A close 
correlation of r = 0.93 was found for the results 
with MAB and PAB. 
Finally, we examined the effect of ibuprofen, 
given at 500 mg p.o. to normal volunteers. TXB2 
was present in serum at a concentration of 100 f 
10 ng/ml. After drug administration TXBz de- 
clined to 1 .O + 0.5 ng/ml at the time (60-120 min) 
of peak ibuprofen plasma levels (n = 3). 
4. DISCUSSION 
We have shown that it is possible to produce 
MABs against TXB2 which are highly selective in 
comparison to PABs. TXB2 metabolites as 
2,3-dinor-TXB2 are less than 10% crossreactive 
with our MAB. This is in contrast to results with 
PABs which show considerable crossreactivity 
with this metabolite (Anhut, personal communica- 
tion [ 141, and anti-TXB2 antibody TRK 780 Amer- 
sham, assayed in our laboratory). PABs against 
TXB2 also show a relatively high degree (up to 
13%) of crossreactivity with PGDz [ 14,151, 
48 
Volume 232, number 1 FEBS LETTERS May 1988 
whereas the MAB-TXB2 shows less than 0.1% 
crossreactivity. The ability to detect low amounts 
of TXB2 in conventional fluid phase RIAs allows 
for the substitution of PABs by this MAB-TXB2 in 
many assays. This can be advantageous due to the 
low crossreactivity particularly with respect to 
chemical substances with a similar ring structure or 
with a side chain similar to TXB2. In addition, we 
have shown that our MAB may be used in routine 
RIA measurement procedures. Comparing the 
MAB with a commercial PAB in macrophage ex- 
periments we obtained good correlation (r = 
0.96-0.98). The fact that both antibodies used in 
fluid phase RIA systems howed differences in the 
absolute quantities of TXB2 measured in the tissue 
culture supernatants did not influence the deter- 
mination of the inhibition range of the drugs, e.g. 
IGO. Although differences were observed, they re- 
main within the usual range of statistical error, 
DIlso 2&7 Indmthacin 
possibly caused by the different characteristics of 
the MAB and the PAB and the different RIA 
methods. It would be of interest to determine the 
significance of the differences using independent 
analytical methods such as W/MS. Finally, as we 
are in a position to produce this MAB in almost 
unlimited quantity and as its characteristics will 
not change from batch to batch as happens with 
PABs it may be of use in standardizing experimen- 
tal results involving the measurement of TX 
metabolites. 
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Fig.3. Effect of indomethacin and dazmegrel on A23187 (10m6 M)-stimulated release of TXAZ (measured in terms of TXBJike 
activity) by mouse peritoneal macrophages using MAB-TXB2 (4E-TBR1) and polyclonal antiserum TRK 780 (Amersham) in different 
fluid phase RIA systems. One representative xperiment with 5 culture dishes for each dose. 
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